Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
News and updates for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) focus on its activities in neurological and rare diseases, including commercial performance and clinical development. Company press releases highlight revenue trends from its marketed medicines NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as guidance ranges for total revenues and net product sales.
Investors following ACAD news can see announcements of quarterly financial results, participation in major healthcare and investor conferences, and business updates presented at events such as the J.P. Morgan Healthcare Conference. These updates often describe how NUPLAZID and DAYBUE are performing commercially and how Acadia views the growth outlook for its neurology and neuro‑rare franchises.
Acadia’s news flow also covers regulatory and clinical milestones. Examples include U.S. Food and Drug Administration approval of DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in adults and pediatric patients 2 years of age and older, approval of DAYBUE oral solution by the Ministry of Health in Israel, and progress toward regulatory opinions and late‑stage studies for trofinetide in other regions. The company issues updates on its pipeline, such as timelines for Phase 2 and Phase 3 trials of remlifanserin (ACP‑204) in Alzheimer’s disease psychosis and Lewy body dementia psychosis, and data presentations on ACP‑711 and NUPLAZID at scientific congresses.
Readers of this ACAD news page can use it to track Acadia’s financial disclosures, regulatory approvals, clinical trial readouts, and strategic commentary from management over time. The news archive provides context on how the company’s commercial portfolio and pipeline in central nervous system and neuro‑rare diseases are evolving.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in three upcoming investor conferences in September 2025. The company will present at the Morgan Stanley Global Healthcare Conference (Sept. 8), H.C. Wainwright Global Investment Conference (Sept. 9), and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Sept. 18).
Acadia specializes in neurological and rare diseases, having developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their current clinical pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis. Live webcasts of the presentations will be available on acadia.com with recordings accessible for approximately one month.
Acadia Pharmaceuticals (Nasdaq: ACAD) has appointed Konstantina "Tina" Katcheves as Senior Vice President, Chief Business and Strategy Officer. Reporting to CEO Catherine Owen Adams, Katcheves will lead the company's business development and corporate strategy initiatives.
Katcheves brings over 20 years of biopharmaceutical industry experience, most recently serving as Senior Vice President, Global Business Development at Teva Pharmaceuticals. At Bristol Myers Squibb, she led the $14 billion acquisition of Karuna Therapeutics and drove more than $18 billion in announced transactions. She previously held senior roles at Agilent Technologies and Lonza Group.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to 26 new employees under its 2024 Inducement Plan, as approved by the Compensation Committee. The awards include 63,477 non-qualified stock options at an exercise price of $23.64 per share and 49,377 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining 50% in two equal annual installments. All awards are subject to continued employment with Acadia.
Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. The company continues to focus on neuroscience and neuro-rare diseases, including programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported strong Q2 2025 financial results with total revenues of $264.6 million, up 9% year-over-year. The company's two key products showed solid growth: NUPLAZID sales increased 7% to $168.5 million, while DAYBUE sales grew 14% to $96.1 million.
The company reported net income of $26.7 million ($0.16 per share) and raised its NUPLAZID 2025 sales guidance to $665-690 million. Acadia maintained strong cash position of $762 million and expects top-line results from its COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025.
Notable achievements include patent litigation wins securing NUPLAZID market exclusivity until 2038 and reaching a record high of 987 unique DAYBUE patients in Q2.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 13, 2025, at 2:30 p.m. Eastern Time. The company will engage in a fireside chat that will be accessible via webcast on Acadia.com's investor section.
Acadia is notable for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. The company's pipeline includes clinical-stage programs focusing on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) has appointed Scott Cenci as Senior Vice President, Chief Information and Data Officer. Cenci, who will report to CEO Catherine Owen Adams, brings over 25 years of experience in pharmaceutical and biotechnology industries.
In his previous role at Genmab, Cenci led the transformation of IT operations, supporting the company's growth from 500 to 2,700 employees and revenue expansion from $750 million to over $3 billion. His extensive experience includes leadership positions at Biogen, Zoetis, and Pfizer, where he specialized in digital transformation, AI initiatives, and global IT operations.
Acadia Pharmaceuticals (NASDAQ: ACAD) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
Acadia is a biopharmaceutical company focused on neurological and rare diseases, notably known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the U.S. and Canada. Their pipeline includes clinical-stage programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to seventeen new employees under its 2024 Inducement Plan. The awards include 35,607 non-qualified stock options at an exercise price of $21.24 per share and 29,571 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment.
Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome, with ongoing clinical-stage development focused on Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (NASDAQ:ACAD) hosted its inaugural R&D Day to showcase its pipeline programs and growth strategy. The company plans to initiate seven Phase 2 or Phase 3 studies during 2025-2026, with five key readouts anticipated by 2027.
Key pipeline highlights include ACP-101 for Prader-Willi syndrome, ACP-204 for Alzheimer's and Lewy Body Dementia Psychosis, ACP-211 for major depressive disorder, ACP-711 for Essential Tremor, and ACP-271 for Tardive Dyskinesia and Huntington's Disease. The company's commercial franchises are expected to generate over $1 billion in net sales this year.